Pharma Exclusives Pressreleases
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
Friday, June 27, 2025Bristol Myers Squibbtoday announced that the US Food and Drug Administration FDA has approved label updates for both of its CAR T cell therapies Breyanzi lisocabtagene maraleucel lisocel for the treatment of large
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
Wednesday, June 25, 2025Gilead Sciences Incand Kymera Therapeutics Inc NASDAQ KYMR today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization
Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
Tuesday, June 24, 2025Datroway has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFRmutated nonsmall cell lung cancer NSCLC who have received prior EGFRdirected therapy and platinumbased chemotherapy
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Monday, June 23, 2025Eli Lilly and Companytoday announced detailed results from QWINT QWINT and QWINT Phase clinical trials evaluating the safety and efficacy of investigational onceweekly insulin efsitora alfa efsitora
Merck Announces Phase 3 HYPERION Study of WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Recently Diagnosed Adults with Pulmonary Arterial Hypertension (PAH)
Monday, June 23, 2025Merck known as MSD outside of the United States and Canada today announced positive topline results from the Phase HYPERION study evaluating WINREVAIR sotaterceptcsrk versus placebo
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Monday, June 23, 2025Biomea Fusion Inc a clinicalstage diabetes and obesity medicines company today announced the presentation of new preclinical and clinical data for icovamenib the companys investigational oral menin inhibitor
Thermo Fisher Scientific Awarded $94.5 Million U.S. Government Contract to Supply the Navy with Advanced Radiation Detection Systems
Monday, June 23, 2025Thermo Fisher Scientific the world leader in serving science today announced that it has been awarded a fiveyear million contract by the US Department of Defense DoD to supply the Navy with a nextgeneration
Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger
Monday, June 23, 2025Dr Ashleys Limited a Hong Kong based global pharmaceutical company and Impact BioMedical Inc a Texas based biopharmaceuticals developer listed on the New York Stock Exchange American are pleased to announce the execution of a merger and share exchang...
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer
Thursday, June 19, 2025The first patient has been dosed in the IDeateProstate phase trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan IDXd versus docetaxel in patients with metastatic castrationresistant
Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia
Thursday, June 19, 2025Biogen Incannounced the initiation of dosing in the BRAVE study a global Phase clinical trial The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia FA
